lung cancer
Conditions
Interventions
Large division group A:Androtinib 12mg / D
Large division group B:Androtinib 10mg / D
General split C:Androtinib 12mg / D
General segmentation D:Androtinib 10mg / D
Sponsors
Shanghai Pulmonary Hospital Affiliated to Tongji University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. ECoG score is 0-1; 2. NSCLC in iiia-iiib stage (the 8th edition of AJCC) with histological or cytological confirmation; 3. Expected survival time >= 12 weeks; 4. Good blood function: hemoglobin >= 100g / L, platelet >= 10 x 10^9 / L, neutrophil absolute count >= 1.5 x 10^9 / L; 5. Liver function: serum bilirubin = 60ml / min; 7. Follow up the protocol and follow-up procedure, and be able to take oral medication; 8. Patients of childbearing age agree to use reliable methods of contraception before entering the study, during the study and within 90 days after drug withdrawal; 9. The subjects volunteered to join the study and signed the informed consent form. They had good compliance and cooperated with the follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with small cell lung cancer; 2. Patients with cancer other than NSCLC within 5 years before the treatment of this study; 3. Received cancer treatment; 4. The patients' compliance to this study was poor; 5. Any unstable systemic disease; 6. Long term uncured wound or fracture; 7. Severe weight loss (more than 10%) occurred in the first 6 weeks; 8. The events of arteriovenous thrombosis occurred in the first 12 months of randomization, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc; 9. Have a history of immune deficiency, or other acquired or congenital immune deficiency diseases, or have a history of organ transplantation; 10. Any disease, metabolic disorder, or physical examination or laboratory suspected that the patient had a contraindication of the study drug or a high risk factor for treatment complications. 11. Other conditions judged by the researchers that are not suitable for inclusion in the study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Security;Total survival;Quality of life;Objective response rate;Disease control rate; | — |
Primary
| Measure | Time frame |
|---|---|
| Disease progression free survival; | — |
Countries
China
Contacts
Public ContactCai Yong
Shanghai Pulmonary Hospital Affiliated to Tongji University
Outcome results
None listed